A clinical comparison of sermorelin and tesamorelin (Egrifta) covering titration protocols, tolerability profiles, IGF-1 response, and how to decide between the two peptides.
A clinical comparison of sermorelin and tesamorelin (Egrifta), with evidence-based guidance on when to switch, why one may fail, and what comes next.
A clinical comparison of tesamorelin (Egrifta) and ibutamoren (MK-677) covering mechanisms, trial data, failure modes, and evidence-based switching protocols for patients and prescribers.
A head-to-head comparison of BPC-157 and GHK-Cu peptides covering mechanisms, clinical and preclinical evidence, dosing, safety, and how to decide which peptide fits your goals.
A clinical head-to-head of BPC-157 vs GHK-Cu across athletes, older adults, post-surgical patients, and other special populations, with trial data, dosing tables, and switching guidance.
A thorough, citation-dense comparison of BPC-157 and TB-500 covering mechanisms, injury repair, dosing protocols, safety signals, and when to switch, prepared by the HealthRX.com Editorial Team.
A head-to-head clinical comparison of TB-500 (thymosin beta-4 fragment) and GHK-Cu (copper tripeptide) for long-term tissue repair, wound healing, and recovery durability. prepared by the HealthRX.com Editorial Team.
A detailed clinical comparison of TB-500 (thymosin beta-4 fragment) and GHK-Cu (copper tripeptide) across athletes, older adults, post-surgical patients, and other special populations, with dosing, evidence, and switching guidance.
A clinical comparison of TB-500 (thymosin beta-4 fragment) and GHK-Cu (copper tripeptide) covering titration protocols, tolerability profiles, mechanism of action, and switching guidance for patients and prescribers.
A clinical comparison of AOD-9604 and MOTS-c, including the evidence base for each peptide, the rationale for combining them, and the risks clinicians and patients need to understand before stacking.
A direct clinical comparison of AOD-9604 (HGH fragment 176-191) and MOTS-c across special populations including older adults, diabetic patients, and athletes. Learn which peptide fits your clinical profile.
A clinical comparison of PT-141 (bremelanotide) and AOD-9604 covering mechanism, durability of effect, dosing, safety, and when switching between the two peptides makes sense.
PT-141 and AOD-9604 target completely different biological systems. When one peptide fails to deliver results, understanding why, and whether to switch, requires knowing how each works, who responds to each, and what the clinical evidence actually shows.
A direct clinical comparison of PT-141 (bremelanotide) and epitalon tetrapeptide, covering mechanism, trial data, real-world outcomes, dosing, and when a switch between the two makes sense.
A clinical comparison of PT-141 (bremelanotide) and MOTS-c across special populations including women with HSDD, older adults, metabolic patients, and athletes. Dosing, safety, and switching guidance backed by primary trials.
A clinical comparison of PT-141 (bremelanotide) and MOTS-c peptides, covering mechanisms, trial data, failure patterns, and evidence-based switching protocols for patients and prescribers.
A clinical comparison of PT-141 (bremelanotide) and thymosin alpha-1, covering their distinct mechanisms, evidence base, combination rationale, and safety considerations for patients and prescribers.
A clinical deep-dive comparing Thymosin Alpha-1 (thymalfasin) and MOTS-c mitochondrial peptide across mechanisms, trial data, real-world outcomes, and patient selection criteria for peptide therapy.
A detailed clinical comparison of dutasteride (Avodart) and isotretinoin (Accutane) covering titration protocols, tolerability profiles, side-effect timelines, and which drug fits which patient.
A head-to-head clinical comparison of dutasteride (Avodart) and spironolactone covering titration protocols, side-effect profiles, onset of effect, and which patients do better on each drug for skin and hair indications.
A head-to-head clinical comparison of dutasteride (Avodart) and topical minoxidil 5% for androgenetic alopecia, covering trial data, long-term durability, and how to choose between them.
A clinical comparison of finasteride and dutasteride (Avodart) for long-term hair retention, covering DHT suppression data, head-to-head trial results, and guidance on when switching makes sense.
A detailed clinical comparison of finasteride and dutasteride (Avodart) across special populations including older men, women, adolescents, and patients with metabolic or kidney disease. Covers efficacy, safety, dosing, and switching guidance.
A direct clinical comparison of finasteride and isotretinoin (Accutane) for long-term durability of response, covering trial data, relapse rates, retreatment protocols, and how to choose the right agent for hair loss versus acne.
A clinical comparison of finasteride and oral minoxidil for androgenetic alopecia, including the evidence for combining both drugs, dosing, side-effect profiles, and who should consider each option.
Finasteride shows durable hair count gains through 5+ years; oral minoxidil's long-term data beyond 2 years remain limited by comparison.
A clinical comparison of finasteride and low-dose oral minoxidil for hair loss across special populations, including women, older adults, and patients with cardiovascular or hormonal conditions. Includes trial data, dosing, and switching guidance.
A detailed clinical comparison of finasteride and spironolactone for hair loss and acne, covering long-term durability, relapse rates, switching protocols, and which drug holds its effect longest.
A head-to-head comparison of finasteride and spironolactone for acne, hair loss, and androgenic skin conditions, drawing on clinical trials, real-world cohort data, and current prescribing guidelines.
A clinical comparison of finasteride and topical minoxidil for androgenetic alopecia, with evidence-based guidance on what to do when one treatment stops working or causes side effects.
A clinical deep-dive comparing finasteride and tretinoin, explaining why they are used together for hair loss and skin aging, what the evidence shows, and what risks to watch for.
A head-to-head clinical comparison of finasteride and tretinoin on long-term durability of response for hair loss and skin aging, with trial data, dosing, and switching guidance.
A head-to-head comparison of oral low-dose minoxidil and dutasteride (Avodart) for hair loss, drawing on clinical trials, real-world cohort data, and current prescribing guidelines to help patients and clinicians choose the right agent.
A clinical comparison of oral minoxidil and dutasteride (Avodart) for hair loss, including what evidence says about switching, combining, or escalating therapy when one drug stops working.
A clinical comparison of oral minoxidil and spironolactone for hair loss and hormonal acne, examining what is actually established about long-term durability, switching and combination protocols, and which patients are candidates for each drug.
A head-to-head comparison of oral minoxidil and spironolactone for hair loss and acne, covering mechanisms, real-world trial data, dosing, side effects, and how to choose between them.
A clinical comparison of oral minoxidil and spironolactone for hair loss and acne, with a decision framework for switching, combining, or escalating when first-line therapy fails.
Oral minoxidil starts at 0.625-2.5mg with faster tissue levels; topical 5% needs twice-daily use. Compare dosing, onset, and side effects.
A head-to-head clinical comparison of oral minoxidil and topical tretinoin examining long-term durability, shedding timelines, relapse rates, and when to switch or combine.
A detailed clinical comparison of oral low-dose minoxidil and topical tretinoin, covering mechanism, efficacy data, side-effect profiles, and how to decide which treatment fits your skin or hair goals.
A clinical comparison of oral minoxidil and tretinoin for hair loss and skin aging. Learn what the evidence says about switching, combining, or escalating when your current treatment stops working.
A clinical comparison of topical minoxidil and isotretinoin (Accutane), covering why dermatologists sometimes combine them, what the evidence says, and how to manage the real risks of concurrent use.
A head-to-head comparison of topical minoxidil 5% and oral/topical spironolactone for hair loss and hormonal acne, grounded in clinical trials and real-world evidence.
A comparison of tretinoin (topical retinoid) and dutasteride (Avodart) across skin, hair, and aesthetics indications, with real-world trial data, dosing, and guidance on when to switch or combine.
A comparison of tretinoin and isotretinoin covering mechanism, indications, combination rationale, and real risks. Includes trial data, dosing guidance, and a decision framework for switching or combining.
A clinical comparison of tretinoin and spironolactone for acne, covering titration protocols, tolerability profiles, onset timelines, and how to decide between them or combine both.
A clinical comparison of tretinoin and topical minoxidil for long-term durability, covering mechanism, trial data, dropout rates, and how to choose between them.
A clinical comparison of Addyi (flibanserin) and Vyleesi (bremelanotide) for hypoactive sexual desire disorder, including mechanism, trial data, switching rationale, combination therapy risks, and prescribing guidance.
A head-to-head clinical comparison of flibanserin (Addyi) and bremelanotide (Vyleesi) for hypoactive sexual desire disorder, covering trial data, durability of effect, switching criteria, and real-world outcomes.
A comparison of Addyi (flibanserin) and Vyleesi (bremelanotide) for hypoactive sexual desire disorder, covering trial data, real-world outcomes, side-effect profiles, and switching guidance.
A head-to-head clinical comparison of flibanserin (Addyi) and bremelanotide (Vyleesi) covering titration schedules, tolerability profiles, and guidance on switching, prepared by the HealthRX.com Editorial Team.
Flibanserin (Addyi) and bremelanotide (Vyleesi) treat HSDD through different mechanisms. When one fails, the other may succeed. Learn the clinical criteria for switching, the trial data behind each drug, and the step-by-step protocol HealthRX.com clinicians use.
Compare flibanserin (Addyi) and bremelanotide (Vyleesi) side-effect profiles, clinical trial data, dosing, contraindications, and which drug may suit different patients with HSDD.
A guide to the most common conditions that co-occur with established cardiovascular disease, how they interact, and what the evidence says about managing them together.
Evidence-based nutrition and lifestyle protocols for adults with established cardiovascular disease, including post-MI, stroke, PAD, and symptomatic CAD. Covers dietary patterns, physical activity targets, weight management, and GLP-1 therapy based on current AHA, ADA, and ACC guidelines.
Evidence-based nutrition and lifestyle protocols for managing menopause-related weight gain, covering dietary strategies, exercise prescriptions, HRT interactions, and GLP-1 options. prepared by the HealthRX.com Editorial Team.
AACE, ADA, and Endocrine Society allow obesity drugs at BMI ≥30, or BMI ≥27 with a comorbidity. See how guidelines compare on thresholds and treatment eligibility.
A head-to-head comparison of PCOS diagnosis and treatment guidelines from the ADA, AACE, Endocrine Society, and the 2023 International Evidence-Based Guideline, with dosing, drug names, and cited trials.
A head-to-head comparison of prediabetes diagnostic thresholds, treatment targets, and pharmacotherapy recommendations from ADA, AACE, the Endocrine Society, and USPSTF, with primary-source citations and clinical decision guidance.
Practical guidance for caregivers and family members supporting someone with tendinopathy, including treatment options, home exercise protocols, red flags, and when to seek specialist care.